In 2013, Vizeacoumar et al [48] performed a genome-wide screen to uncover negative genetic interactions (i.e. SL interactors) across a set of isogenic cancer cell lines, including the BLM-deficient cells employed in the current study. This evidence concerns the gene BLM and cancer.